...
首页> 外文期刊>Journal of bone and mineral metabolism >Effect and safety of intermittent weekly administration of human parathyroid hormone 1-34 in patients with primary osteoporosis evaluated by histomorphometry and microstructural analysis of iliac trabecular bone before and after 1 year of treatment.
【24h】

Effect and safety of intermittent weekly administration of human parathyroid hormone 1-34 in patients with primary osteoporosis evaluated by histomorphometry and microstructural analysis of iliac trabecular bone before and after 1 year of treatment.

机译:通过治疗1年前后after骨小梁骨的组织形态计量学和显微结构分析,评估了每周一次间歇性施用人甲状旁腺激素1-34在原发性骨质疏松症患者中的效果和安全性。

获取原文
获取原文并翻译 | 示例

摘要

In order to evaluate the efficacy and safety of intermittent subcutaneous administration of 1-34 N-terminal peptide of human parathyroid hormone (hPTH 1-34), 100 units of hPTH 1-34 was subcutaneously injected once a week for 1 year in ten patients with primary osteoporsis (one male and nine females) with no qualitative abnormality of the bone according to the results of iliac crest biopsy performed previously, followed by a second biopsy after the end of the 1-year administration. Written consent of the patients for participation in the study was obtained. The mean lumbar bone mineral density (LBMD) definitely increased, by 1.8%, 3.4%, and 4.6% after 12, 24, and 48 weeks of hPTH administration, in accordance with previous clinical studies. Histomorphometric analysis after double-tetracycline labeling was completed in six patients (one male and five females) after the exclusion of those who dropped out because of adverse events unrelated to the test drug, or refusal of continuation. Examination of thin hard-tissue sections revealed no qualitative abnormalities of bone tissue or bone marrow cavity, such as osteomalacia, woven bone, or osteitis fibrosa, precluding the contribution of qualitatively abnormal tissue elements to any changes of LBMD in response to hPTH 1-34 administration. Histomorphometric measurement in the second biopsy revealed a tendency for an increase of bone volume, a significant increase of osteoid surface, and a tendency for an increase in other parameters of bone formation, compared with values obtained in the preadministration biopsy. Indices of two-dimensional microstructure obtained by microfocus computed tomography (CT) and results of node-strut analysis indicated improvement of trabecular continuity. In five patients in whom three-dimensional reconstruction images were analyzed, there were significant increases of bone volume and trabecular thickness, and a significant decrease in the trabecular bone pattern factor, a parameter related to the continuity, suggesting an improvement of the three-dimensional trabcular microstructure. Intermittent weekly subcutaneous injections of hPTH (1-34) for 48 weeks increased trabecular bone volume and improved microstructure, without causing the appearance of abnormal bone elements in primary osteoporosis.
机译:为了评估间歇性皮下注射人甲状旁腺激素的1-34 N端肽(hPTH 1-34)的有效性和安全性,十名患者每周一次皮下注射100单位的hPTH 1-34,持续1年根据先前进行的c c活检的结果,原发性骨质疏松症(一男一女,九名女性)的骨质没有异常,在1年给药结束后进行第二次活检。获得患者参与研究的书面同意。根据先前的临床研究,在给予hPTH 12、24和48周后,平均腰骨矿物质密度(LBMD)确实增加了1.8%,3.4%和4.6%。在排除因与试验药物无关的不良事件或拒绝继续治疗而退学的患者后,对六例患者(一男五女)进行了双四环素标记后的组织形态计量学分析。对薄薄的硬组织切片的检查未发现骨组织或骨髓腔(如骨软化症,编织的骨或纤维性骨炎)的定性异常,排除了质变异常的组织元素对响应hPTH 1-34的LBMD的任何改变的贡献行政。与给药前活检相比,第二次活检的组织形态计量学测量显示出骨量增加,类骨质表面显着增加以及其他骨形成参数增加的趋势。通过微焦点计算机断层扫描(CT)获得的二维显微结构指标和结点支撑分析结果表明,小梁连续性得到改善。在分析了三维重建图像的五位患者中,骨体积和小梁厚度显着增加,而小梁骨模式因子(与连续性相关的参数)显着降低,表明三维三维结构得到了改善小梁的微观结构。每周48h间歇性每周皮下注射hPTH(1-34)可增加小梁的骨体积并改善微结构,而不会引起原发性骨质疏松症中异常骨元素的出现。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号